The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. - Wikidata - wikimedia - TriplyDB

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.

http://www.wikidata.org/entity/Q36058010

about

Erythropoietin: new directions for the nervous system Cutting through the complexities of mTOR for the treatment of stroke Targeting the intragraft microenvironment and the development of chronic allograft rejection Targeting disease through novel pathways of apoptosis and autophagy Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cells Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.The FOX transcription factors regulate vascular pathology, diabetes and Tregs Targeted therapies for pancreatic cancer.Myeloid-derived suppressor cells are involved in lysosomal acid lipase deficiency-induced endothelial cell dysfunctions.Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells.PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection Overnutrition, mTOR signaling, and cardiovascular diseases.The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.Effect of antibodies on endothelium.Protection of porcine endothelial cells against apoptosis with interleukin-4.Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo.Rapamycin impairs endothelial cell function in human internal thoracic arteries.Cardiovascular disease and mTOR signaling mTOR-understanding the clinical effects.Hypoxia-inducible factor 1-α-AA-modified bone marrow stem cells protect PC12 cells from hypoxia-induced apoptosis, partially through VEGF/PI3K/Akt/FoxO1 pathway.Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway.Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses.Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts.mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.β-Elemene: Mechanistic Studies on Cancer Cell Interaction and Its Chemosensitization Effect Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

P2860

Q26828425-7FBF5E0D-7C74-4A95-8E03-477A60B35617 Q26851291-09A4D719-58DB-457C-B91F-B5D981D8EDEA Q26852762-83F73A53-7DDC-470D-B23F-DFAD950D190F Q26864639-9A923EA1-6027-44FC-BC80-0DBB625FB59B Q27015640-5CCC3CE9-43A2-4036-BA7E-44BCB74ACF4B Q28576589-F800FF1F-F9B0-4D1D-B9ED-CAF4D69995F9 Q33412198-725CFB8C-2ED9-40BC-9D3D-EB4FB7AB8C35 Q33422258-88B7D49B-693F-4C15-A709-2E8FFB6FBEB0 Q33763033-F4E91D1A-5B09-4B2A-95F2-47A1F9252AE0 Q33899923-4ADAAE8A-EF12-4504-8F60-88B409EC06A5 Q33992611-16EBCFD5-A3C5-4714-B3CE-9224FFE716B3 Q34385792-03B54AA3-8DB0-4940-9714-422082FF39B2 Q34429082-BC93C2DA-3180-468F-BF63-CC144FFB3EDA Q34519316-0B50B36B-CEEB-4D0F-A756-7E7999AB5140 Q34924913-CCB019D0-30FD-4899-993C-E3A616AED975 Q35157985-788ED924-6605-4DBB-BF73-75C6B5CBF9F2 Q35177682-321C1750-9619-4B26-8DFE-40AC0247A779 Q35547335-77103507-561E-4927-88B9-BA1038E7BECF Q35688135-9240E344-4D32-481A-84B4-1DFB5E8592C2 Q35820068-84BF7A26-5654-4B75-BE54-CBB79452921E Q35834072-86BE29DD-5FCC-4695-8AF9-71BD646319EC Q35852325-6ECBC9AC-F537-40C6-B5D7-6B9D06915B66 Q36062316-DB6D15AA-4629-44E5-B82B-7696968415B7 Q36084504-C595ADA9-930B-4195-9514-EFF4EC505AD0 Q36225357-20B73D7D-8F92-4E43-A957-909E3117DC6E Q36318871-B61415CA-9914-4C9A-A35A-42150FFC9C29 Q36379761-AF8A37B4-C284-4E27-967C-3A3B9B363230 Q36392591-517D4304-A588-477A-8049-C3B027F154EA Q36432388-F2DEABDB-2E7B-4F16-9E51-0B7164BE94AB Q36462135-0E5841EE-1D2D-4C30-B453-119DEDA35284 Q36664510-13EA3647-594A-4471-9776-2E393BB77701 Q36861418-207B7F18-8A6C-448E-B6F7-6A99DCB4E46D Q36905641-FF318F52-FF1F-4EDC-9863-411B878E7B61 Q37132788-CA19ED98-F80B-430C-A6F5-5CC7BBB15CA5 Q37151705-298B972B-7F09-4BC6-81A5-6A3205C06747 Q37445163-C6E2D4C6-7742-481D-8FA7-3705B9B22954 Q37451552-B12E97B6-0BAF-4291-A883-F138383FDBDE Q37689542-4E0BEEA3-F92E-4D44-B0C7-CB17A8621D3E Q37699173-529937F5-85B8-4423-B240-547D9200E156 Q37760379-D51060B4-C2AD-4717-B2E5-DF66ED6355EE

P2860

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.

http://www.wikidata.org/entity/Q36058010

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@ast

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@en

type

label

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@ast

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@en

prefLabel

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@ast

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@en

P1433

Q36058010-3EA26916-D87A-43EA-9040-D9A16372D1F4

P1476

Q36058010-9630B282-3EF5-4B2A-8A81-FC1F17DF2296

P2093

Q36058010-4A089E93-864E-4F3F-9437-2F82C196643F

Q36058010-9E097B7D-BC11-48DC-A046-9D303398108B

Q36058010-B5A093DA-8E06-4A73-9F10-63FE3EC387D8

P2860

Q36058010-0036B153-E2D9-4953-8225-D63E1A0A9939

Q36058010-07A0DB6C-A30A-4C13-AB3B-8542179BE367

Q36058010-12087EF9-D69B-4324-B4F6-A34F59D963CF

Q36058010-127C79DC-96B6-4CD7-8E19-5EF2C185F3AB

Q36058010-1325CD99-B81A-424D-BDF1-6838F9BC5FF1

Q36058010-18C07387-1961-407E-8B1C-7ACD57E560B8

Q36058010-18D456A4-3F15-42C5-AC02-54DBB54E6C42

Q36058010-1F5011E8-51A8-452F-A3FF-1FCB6828CA52

Q36058010-1FABAF8D-52AB-4C19-8C53-F8DECD8C3B06

Q36058010-27E14916-7364-4FC4-BEDE-325D39B172C9

P304

Q36058010-ED3CA23E-BEFF-487C-BF2C-86A65C1F300A

P31

Q36058010-2C40C08B-A1BB-42AC-964E-D0C5AC272E3C

P356

Q36058010-BE4A9398-F63F-44DE-97E2-39656ADF0EDC

P407

Q36058010-4B06C04C-4986-42FA-893E-F47D71FA2FF6

P433

Q36058010-8AC34F0B-8055-4192-A0BF-BEA22498DD3F

P478

Q36058010-69AC2E12-4731-4C2E-9655-9A74EDBD56AF

P577

Q36058010-2223DE45-4F6D-48FA-B04C-A4CD46540549

P5875

Q36058010-D23DB343-0D25-4EF4-B34C-AD3CD91E7283

P698

Q36058010-285DFE78-30F8-44DB-9E5F-8FC4A5F7D9E4

P921

Q36058010-207A3756-7107-45F9-AB0E-C2529E252755

Q36058010-E145C38E-2B14-4A3D-8256-52E589CE567D

P932

Q36058010-22063C39-513C-4858-9077-465E44E20D24

P356

P1433

Journal of Biological Chemistry

P1476

The effects of mTOR-Akt intera ...... in vascular endothelial cells.

@en

P2093

David M Briscoe

http://www.w3.org/2001/XMLSchema#string

Joren C Madsen

http://www.w3.org/2001/XMLSchema#string

Olivier Dormond

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Mechanism of activation of protein kinase B by insulin and IGF-1

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

P304

23679-23686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M700563200

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6282619

http://www.w3.org/2001/XMLSchema#string

P698

17553806

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

3383050

http://www.w3.org/2001/XMLSchema#string